Related Experiment Video
Updated: Jul 17, 2026
06:47
Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
Published on: September 20, 2011
Review article: similarities and differences among delayed-release proton-pump inhibitor formulations
1Department of Pharmacy, University of Washington, Seattle, WA, USA.
Alimentary Pharmacology & Therapeutics
|November 24, 2005
Summary
Delayed-release proton-pump inhibitors (PPIs) have enteric coatings, causing delayed absorption. While minor formulation differences exist, they do not significantly impact clinical outcomes in patients.
Area of Science:
- Pharmacology
- Gastroenterology
Background:
- Proton-pump inhibitors (PPIs) are acid-labile and require enteric coating for oral administration to prevent stomach degradation.
- Enteric coating leads to delayed absorption and onset of action for PPIs.
Purpose of the Study:
- To review similarities and differences between various delayed-release proton-pump inhibitor formulations.
- To evaluate the impact of formulation differences on pharmacokinetics and pharmacodynamics.
Main Methods:
- Review of existing literature on delayed-release proton-pump inhibitor formulations.
- Analysis of pharmacokinetic and pharmacodynamic data for different PPI formulations.
Main Results:
- Delayed-release PPIs, including omeprazole and lansoprazole, show formulation-based pharmacokinetic differences, mainly in initial bioavailability.
- Some formulations, like omeprazole suspended in sodium bicarbonate for tube administration, may have impaired absorption and reduced antisecretory effects.
- Few significant differences exist in pharmacodynamic effects during chronic administration among delayed-release PPIs.
Conclusions:
- Minor pharmacokinetic and pharmacodynamic differences among delayed-release PPI formulations do not result in meaningful differences in clinical outcomes.
- Formulation choices may offer convenience but do not fundamentally alter therapeutic efficacy in the long term.
Related Concept Videos
01:27Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...